Breast carcinoma and antihypertensive therapy: Robbing Peter to Pay Paul?

Cancer

Volumn 98, Issue 7, 2003, Pages 1334-1336

  Giordano, Sharon H ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE; POTASSIUM SPARING DIURETIC AGENT; THIAZIDE DIURETIC AGENT; VASODILATOR AGENT; VERAPAMIL;

ANTIHYPERTENSIVE THERAPY; BREAST CARCINOMA; CANCER RISK; CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CONTROLLED RELEASE FORMULATION; DISEASE ASSOCIATION; DISEASE COURSE; EVIDENCE BASED MEDICINE; HUMAN; HYPERTENSION; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

AGED; ANTIHYPERTENSIVE AGENTS; BREAST NEOPLASMS; CARCINOMA; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; HYPERTENSION; INCIDENCE; MIDDLE AGED; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT;

EID: 0141675140     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11695     Document Type: Review

References (12)

1. William GH. Hypertensive vascular disease. In: Braunwald E, Fauci A, Kasper D, et al., editors. Harrison's principles of internal medicine, 15th ed. New York: McGraw-Hill, Inc., 2001:1414-1430.
2. Pahor M, Guralnik JM, Ferrucci L, et al. Calcium-channel blockade and incidence of cancer in aged populations. Lancet. 1996;348:493-497.
3. Michels KB, Rosner BA, Walker AM, et al. Calcium channel blockers, cancer incidence, and cancer mortality in a cohort of U.S. women: the Nurses' Health Study. Cancer. 1998;83:2003-2007.
4. Fitzpatrick AL, Daling JR, Furberg CD, Kronmal RA, Weissfeld JL. Use of calcium channel blockers and breast carcinoma risk in postmenopausal women. Cancer. 1997;80:1438-1447.
5. Jick H, Jick S, Derby LE, Vasilakis C, Myers MW, Meier CR. Calcium-channel blockers and risk of cancer. Lancet. 1997;349:525-528.
6. Olsen JH, Sorensen HT, Friis S, et al. Cancer risk in users of calcium channel blockers. Hypertension. 1997;29:1091-1094.
7. Rosenberg L, Rao RS, Palmer JR, et al. Calcium channel blockers and the risk of cancer. JAMA. 1998;279:1000-1004.
8. Sorensen HT, Olsen JH, Mellemkjaer L, et al. Cancer risk and mortality in users of calcium channel blockers. A cohort study. Cancer. 2000;89:165-170.
9. Li CI, Malone KE, Weiss NS, Boudreau DM, Cushing-Haugen KL, Daling JR. The relationship between use of antihypertensive medications and risk of breast cancer among women 65-79 years of age. Cancer. 2003;98:1504-1513.
10. World Health Organization. 1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension. J Hypertens. 1999;17:151-183.
11. Black HR, Elliott WJ, Grandits G, et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA. 2003;289:2073-2082.
12. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.